Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 620,000 | 563.6% |
| Gross Profit | -1.5M | 1712.9% |
| Cost of Revenue | 2.1M | 13623.6% |
| Operating expense | 890,000 | 59.2% |
| Net Income | -2.2M | 18.3% |
| EBITDA | -2.4M | 15.1% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 19M | 9.4% |
| Total Liabilities | 1.4M | 11.5% |
| Total Equity | 17M | 10.8% |
| Shares Outstanding | 5.4M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 2M | 200% |
| Cash from investing | 4.5M | 610.2% |
| Cash from financing | 76,000 | 0% |
EPS
Financial Highlights for Lipocine in Q2 '25
Lipocine reported a revenue of 620,000, which is a 563.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -1.5M, marking a -1712.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.1M, a 13623.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 890,000, showing a -59.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.2M, showing a -18.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -2.4M, showing a -15.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Lipocine faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
